- Updated guidance now frames obesity as a central driver of cardiovascular-kidney-metabolic (CKM) syndrome, rather than an isolated risk factor.
- The new guidelines emphasize early identification and intervention, encouraging healthcare professionals to discuss weight management before serious complications develop.
- Specifically, the guidelines highlight the importance of metabolic health and abdominal fat, which can contribute to inflammation, insulin resistance, and damage to the heart, kidneys, and blood vessels.
- Recommended treatment should be comprehensive and coordinated, combining lifestyle changes and medications when appropriate, while improving collaboration among healthcare specialties.
Cardiovascular-Kidney-Metabolic (CKM) syndrome is a complex health disorder linking cardiovascular disease, chronic kidney disease, and metabolic disorders such as type 2 diabetes and obesity. The American Heart Association (AHA)
Evidence suggests that
Many of these factors often coexist and contribute to progressive damage across multiple organ systems. CKM syndrome develops along a continuum, beginning with metabolic risk factors and potentially advancing to significant cardiovascular and kidney disease if left unmanaged.
Now, the first-ever clinical guideline on CKM syndrome from the AHA and the American College of Cardiology (ACC), published in
A shift toward cardiovascular-kidney-metabolic syndrome prevention
The first-ever clinical guideline for CKM syndrome identifies excess weight, especially in the abdomen, as a key driver for the syndrome.
Ace
However, despite highlighting obesity as a key driver, the guideline notes that body weight alone does not tell the whole story. Individuals may have the same body weight, but markedly different health profiles depending on how fat tissue affects metabolic function.
The document highlights abdominal fat, specifically visceral fat, as a particularly important contributor to disease progression.
Excess fat surrounding organs can promote chronic inflammation, insulin resistance, and damage to blood vessels, increasing the likelihood of developing diabetes, kidney disease, heart failure, heart attack, and stroke.
“Visceral fat acts like a metabolically active organ that releases inflammatory signals that contribute to insulin resistance and chronic inflammation over time,” Kevin Shah, MD, board certified cardiologist and Program Director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at Long Beach Medical Center in Long Beach, CA, who was not involved in the guidance, explained to Medical News Today.
“Over time, these changes increase the risk for diabetes, kidney disease, heart disease, heart failure, and CKM. This is one reason waist circumference can sometimes provide additional risk information beyond what body mass index (BMI) can provide.”
—Kevin Shah, MD
Discussing weight as a medical risk for organ damage
The new recommendations replace a
The new guidance encourages healthcare professionals to discuss weight as a medical risk factor that can contribute to organ damage rather than as a cosmetic concern. It also recommends approaching the topic sensitively and collaboratively with patients.
Ideally, it is advisable for healthcare professionals to begin these conversations before serious complications emerge, helping people understand how obesity may contribute to future diabetes, kidney disease, and cardiovascular problems.
Managing CKM: Lifestyle, medication, and healthcare
The guideline highlights healthy lifestyle practices as the foundation of CKM syndrome management. In particular, it advises incorporating the
These are 8 modifiable factors that can help reduce the risk of heart disease and improve overall health. The 8 metrics include regular physical activity, heart-healthy eating patterns, avoiding nicotine exposure, healthy sleep habits, and maintaining a healthy weight, blood glucose, blood lipids, and blood pressure levels.
“The most important step is recognizing the connection between heart, kidney, and metabolic health. Reducing risk can be achieved by maintaining healthy weight, regular exercise, optimizing sleep, avoiding tobacco, and managing conditions such as high blood pressure, diabetes, and cholesterol,” Shah said.
Alongside lifestyle interventions, the guideline recognizes an expanding range of medications that can improve outcomes across multiple organ systems.
Specifically, the therapies highlighted include sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor-based treatments, and nonsteroidal mineralocorticoid receptor antagonists.
These medications have demonstrated benefits extending beyond blood sugar control, including protection of heart and kidney health.
The guideline also focuses on improving coordination among healthcare professionals.
Those living with CKM syndrome often receive care from multiple specialists, including cardiologists, nephrologists, endocrinologists, and primary care physicians. The guideline recommends greater use of care coordinators or patient navigators to help ensure communication among clinicians and improve follow-up care.
As it is rare for a person to experience these conditions one at a time, the guidance advocates for a more holistic model in which healthcare teams work together while patients remain central to decision making.
What the new guideline means for patients and doctors
The guideline reflects a growing recognition that obesity, diabetes, kidney disease, and cardiovascular disease are deeply interconnected and often develop through shared biological mechanisms.
Rather than treating each condition separately after complications arise, the guideline suggests that earlier identification of metabolic risk and proactive management of weight-related health issues could help prevent long-term organ damage.
For patients, the message is that weight management is increasingly being viewed through the lens of overall metabolic health rather than appearance.
For clinicians, the guideline provides a framework for discussing weight, screening for CKM syndrome, and coordinating care across specialties before irreversible complications occur.
Shah is very optimistic that earlier recognition and treatment of CKM syndrome could reduce the burden of these related conditions.
“Traditionally, we treat the conditions of heart disease, kidney disease, obesity, and diabetes as separate conditions. The CKM framework recognizes these are closely linked,” he said.
“Earlier identification (of CKM) can allow clinicians to intervene sooner with lifestyle changes and increasingly impactful therapies that can reduce the long-term risk of cardiovascular events, renal failure, and heart failure.”
—Kevin Shah, MD



